Azenta Inc provides biological and chemical sample exploration and management solutions, using precision automation and cryogenics to develop automated ultra-cold storage. It serves customers from research to commercialization with sample management, automated storage, genomic services, consumables, informatics, and repository services. The company operates through two segments: Sample Management Solutions, offering SRS and Core Products such as automated stores, cryogenic systems, sample tubes, consumables, instruments, and thawing devices, which generate majority of its revenue; and Multiomics, which provides genomic analysis services. The company operates in United States, China, United Kingdom, rest of Europe, and others, with majority of its revenue in the United States.
Last trade$46.63
Day change-$0.595 (-1.26%)
Day range$46.35 – $48.56
Volume742,791
Market cap$1.97B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.97B
Price / earnings
—
Price / book
1.31×
Price / sales
3.21×
EV / sales
2.9×
EV / EBITDA
65.45×
Profitability
Earnings per share
-$2.94
Return on assets
-6.55%
Return on equity
-8.14%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
2.66×
Quick ratio
2.35×
Cash ratio
0.74×
Cash flow
Price / cash flow
51.92×
Price / free cash flow
199.55×
Free cash flow
$9.88M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for AZTA, quarterly periods
Line item
Q3 FY2026 Jun 30, 2026
Q2 FY2026 Mar 31, 2026
Q1 FY2026 Dec 31, 2025
Q4 FY2025 Sep 30, 2025
Q3 FY2025 Jun 30, 2025
Q2 FY2025 Mar 31, 2025
Q1 FY2025 Dec 31, 2024
Q4 FY2024 Sep 30, 2024
Revenue
$161.18M
$144.8M
$148.64M
$158.95M
$143.86M
$143.34M
$147.44M
$151.08M
Cost of revenue
$88.82M
$82.76M
$84.94M
$90.99M
$77.45M
$80.56M
$78.62M
$84.34M
Gross profit
$72.36M
$62.04M
$63.71M
$67.96M
$66.4M
$62.78M
$68.82M
$66.74M
Selling, general and administrative
$67.17M
$67.89M
$60.61M
$55.73M
$60.08M
$69.8M
$69.98M
$60.04M
Research and development
$8.85M
$9.43M
$9.19M
$10.46M
$7.42M
$7.6M
$7.11M
$9.57M
Total operating expenses
$76.53M
$227.83M
$70.94M
$66.59M
$68.25M
$80.98M
$77.52M
$70.46M
Operating income
-$4.18M
-$165.79M
-$7.24M
$1.37M
-$1.85M
-$18.19M
-$8.7M
-$3.72M
Interest expense
$3.83M
$0
$0
$0
$4.97M
$0
$0
$0
Income before taxes
$846K
-$157.34M
-$2.06M
$5.78M
$2.3M
-$12.55M
-$3.2M
$1.21M
Income taxes
$2.38M
-$323K
$3.13M
-$45.61M
$2.64M
$7.24M
$3.87M
$2.02M
Net income
$2.46M
-$160.8M
-$15.43M
$50.84M
-$47.99M
-$47.66M
-$10.99M
-$5.71M
Net income attributable to common shareholders
$2.46M
-$160.8M
-$15.43M
$50.84M
-$47.99M
-$47.66M
-$10.99M
-$5.71M
EBITDA
$9.92M
-$1.28M
$7.55M
$11.04M
$13.63M
-$661K
$9.83M
$14.21M
Basic earnings per share
$0.05
-$3.49
-$0.34
$1.11
-$1.05
-$1.04
-$0.25
-$0.12
Diluted earnings per share
$0.05
-$3.49
-$0.34
$1.09
-$1.05
-$1.04
-$0.25
-$0.12
Recent news
Company coverage with links to the original publishers.
The Rosen Law Firm is investigating potential securities claims on behalf of shareholders of NVE Corporation and Azenta, Inc., alleging that both companies may have issued materially misleading business information to investors. The firm is preparing class action lawsuits seeking recovery of investor losses and encourages affected shareholders to join the prospective class actions.
The Rosen Law Firm is investigating potential securities claims against Azenta, Inc. (NASDAQ: AZTA) following allegations of materially misleading business information. The investigation was triggered by the resignation of President and CEO John P. Marotta on August 22, 2026, which caused Azenta's stock to fall 12% on August 24, 2026. The firm is preparing a class action lawsuit to recover investor losses.
Azenta (AZTA) stock surged 20.80% on Wednesday following strong fiscal Q4 2026 earnings results. The healthcare tech company reported revenue of $167 million (up 5% YoY) and adjusted net income of $0.28 per share, significantly beating analyst expectations of $0.12 per share. The company also provided optimistic guidance for fiscal 2027, projecting revenue between $648-660 million with EBITDA margin expansion of 200-250 basis points.
The Rosen Law Firm is investigating potential securities claims against Azenta, Inc. (NASDAQ: AZTA) following allegations of materially misleading business information. The investigation was triggered by the resignation of President and CEO John P. Marotta on August 22, 2026, which caused Azenta's stock to fall 12% on August 24, 2026. Investors who purchased Azenta securities may be eligible to join a class action lawsuit seeking recovery of losses.
Rosen Law Firm is notifying investors about ongoing securities class action lawsuits against Lincoln Educational Services Corporation (LINC), Qfin Holdings, Inc. (QFIN), and Azenta, Inc. The lawsuit against LINC alleges the company made false statements about its admissions process and student enrollment conversion rates. Investors who purchased securities during specified periods are encouraged to seek counsel, with a November 10, 2026 deadline for lead plaintiff claims.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Dec 2, 2021
$0.10
Dec 23, 2021
recurring
Stock splits
Historical share-structure events and their execution dates.